Related Experiment Video
Updated: Aug 16, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Induced proximity-based therapeutics for advanced prostate cancer
John Ching1, Cindy H Chau2, William D Figg3,4
1Clinical Pharmacology Program, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, US.
Induced proximity therapeutics offer a novel strategy to target androgen receptor (AR) signaling in metastatic castration-resistant prostate cancer (mCRPC). These advanced approaches show promise in overcoming treatment resistance for mCRPC patients.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Metastatic castration-resistant prostate cancer (mCRPC) remains dependent on androgen receptor (AR) signaling.
- Existing therapies targeting AR signaling often face resistance in mCRPC.
Purpose of the Study:
- To review recent advancements in induced proximity strategies for targeting AR in mCRPC.
- To explore the potential of event-driven pharmacology in overcoming AR-related resistance.
Main Methods:
- Review of current literature on induced proximity-based therapeutics.
- Analysis of mechanisms of action for AR-targeting induced proximity agents.
- Discussion of preclinical and clinical data related to these strategies.
Main Results:
- Induced proximity strategies represent a promising therapeutic modality for mCRPC.
- These approaches leverage event-driven pharmacology to enhance AR degradation or inhibition.
- Recent advances show potential for overcoming resistance to conventional AR-targeted therapies.
Conclusions:
- Induced proximity-based therapeutics are emerging as a significant strategy in mCRPC treatment.
- Further research and clinical evaluation are warranted to fully realize the potential of these novel agents.
- Targeting AR signaling through induced proximity may offer new hope for patients with resistant prostate cancer.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy

